Neurokard Sp. z o.o.
- Address
- Aleja Zjednoczonej Europy 37, 44-240 Żory, Poland
Neurokard Sp. z o.o. - Multiple Sclerosis Research Center
Neurokard Sp. z o.o. is a specialized clinical research center focused on advancing therapeutic options for patients with relapsing forms of multiple sclerosis (RMS). The center demonstrates particular expertise in conducting phase II and III clinical trials evaluating novel disease-modifying therapies, with a strong emphasis on comparative effectiveness studies against established treatment standards.
- Novel immunomodulatory agents targeting neuroinflammation in relapsing multiple sclerosis
- Comparative efficacy studies using annualized relapse rate (ARR) as primary outcome measures
- Advanced neuroimaging assessments including T1 gadolinium-enhancing MRI brain lesion monitoring
The center's research portfolio includes evaluation of cutting-edge therapies such as BTK inhibitors, CD40L antagonists, and other targeted immunotherapies. With extensive experience in sophisticated endpoint assessment including MRI lesion quantification and relapse rate measurements, Neurokard provides comprehensive clinical trial support for pharmaceutical companies developing next-generation multiple sclerosis treatments.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Merz Therapeutics GmbH2active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merz Therapeutics GmbH2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Neurokard Sp. z o.o.
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH TERIFLUNOMIDE IN ADULT PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS | F. Hoffmann-La Roche AG | Phase III | Not Recruiting | Dec 2020 | — |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins | 2 | Unknown | 2025-10-06 | 2025-10-06 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.